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Abstract 
Obstructive sleep apnea (OSA) syndrome is a condition characterized by the presence of complete or partial col-
lapse of the upper airways during sleep, resulting in fragmentation of sleep associated with rapid episodes of in-
termittent hypoxia (IH) and activation of the sympathetic nervous system and oxidative stress. (Dempsey et al. 
2010, 47–112; Bradley and Floras 2003, 1671–78; Bradley and Floras 2009, 82–93). OSA is associated with a 
broad spectrum of cardiovascular, metabolic, neurocognitive and comorbidities that appear to be particularly ev-
ident in obese patients (Floras 2014, 3–8; Luz Alonso-Álvarez et al. 2011, 0, 2–18; Marcus et al. 2012, e714–55; 
Sforza and Roche 2016, 99), while affecting both sexes in a different manner and varying in severity according to 
gender and age (Mokhlesi, Ham and Gozal 2016, 1162–69). In recent years, studies on OSA have increased con-
siderably, but in clinical practice it is still a highly underdiagnosed disease (Costa et al. 2015, 1288–92). To date, 
the gold standard for the diagnosis of OSA is nocturnal polysomnography (PSG). However, since it is not well 
suited to a large number of patients, also the Home Sleep Test (HST) is an accepted diagnostic method.   
Currently, the major aim of the research is to identify non-invasive methods to achieve a highly predictive, non-
invasive screening system for this category of subjects. The most recent reports indicate that research in this field 
has made significant progress in identifying possible biomarkers in OSA, using -OMIC approaches, particularly 
in the field of proteomics and metabolomics. In this review, we analyze a list of these OMIC biomarkers found 
in literature. 
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Incidence of OSA 
 
Despite its high prevalence and the high burden 
of morbidity, Obstructive Sleep Apnea (OSA) 
remains a significantly underdiagnosed disease 
worldwide. The Hypnolaus study estimated that 
the prevalence of moderate-to-severe sleep-
disordered breathing (≥15 events per h) was 
23.4% (95% CI 20·9–26.0) in women and 
49.7% (46.6–52.8) in (Heinzer et al. 2015, 310–
8) whereas according to the American Academy 
of Sleep Medicine (AASM 2016), only 20% of 
patients are diagnosed (about 6 million out of a 
total of 24 million) in US. The annual cost for 
an undiagnosed patient is estimated to be at 
around $5,500 (considering direct and indirect 
health costs), while it drops to $2,100 per year 
for diagnosed patients (Pietzsch et al. 2011, 
695–709). On this basis, it is evident that OSA 
is not only a serious health problem, but also a 
socio-economic problem.  
OSA is also becoming dangerously frequent in 
children, associated with adenotonsillar hyper-
trophy (Capdevila et al. 2008, 274–82; Lumeng 
and Chervin 2008, 242–52) as well as high rates 
of overweight and obesity in children in west-
ern countries. These trends will have disastrous 
long-term consequences for global health and 
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life expectancy if solutions are not taken as 
soon as possible to correct erroneous lifestyles 
from the earliest age (Bixler et al. 2009, 731–36; 
L Kheirandish-Gozal and Gozal 2012, 713–14; 
Li et al. 2010, 991–97; Marcus et al. 2012, e714–
55). 
These data also suggest that the only way to 
make sustainable the costs of OSA is the pre-
vention. 
 
Pathogenic mechanisms associated with 
OSA 
 
OSA is considered by far the most important 
form of sleep disturbance in breathing. It is 
caused by increased collapsibility or insufficien-
cy/loss of muscular dilation capacity of the up-
per airways, leading to repeated pharyngeal 
constriction (hypopnea) or closure (apnoea), 
and therefore resulting in oxyhemoglobin satu-
ration decreasing and partial pressure of carbon 
dioxide in arterial blood increasing (Jordan, 
McSharry and Malhotra 2014, 736–47).  
To date, the gold standard for the diagnosis of 
OSA is nocturnal polysomnography (PSG). 
This sleep examination utilizes electroenceph-
alography, electrooculography in both eyes, 
sub-mental electromyography, nasal airflow, 
snoring sounds, electrocardiography, thorac-
ic/abdominal movements, pulse oxygen satura-
tion and body position to measure various pa-
rameters. The PSG indices included were the 
apnoea-hypopnoea index 
(AHI) and oxygen desaturation index. Howev-
er, since it is not well suited to a large number 
of patients, also the Home Sleep Test (HST) is 
an accepted diagnostic method.   
To restore pharyngeal patency, patients experi-
ence recurrent awakenings, resulting in frag-
mented sleep, followed by reduced cognitive 
performance and, in some cases, diurnal sleepi-
ness episodes.  
High circumference values of the neck, hips 
and waist, hypertension (HTN), usual nocturnal 
snoring, as well as presence of a diabetic condi-
tion and a high body mass index (BMI) are of-
ten coexisting conditions in the OSA patient at 
the time of diagnosis. Among these comorbidi-
ties, obesity is often the worst aggravating fac-
tor, leading to the activation of molecular 
mechanisms that, if not effectively and early 
identified, may worsen the overall clinical pat-
tern of OSA.  
In the literature, substantial evidence suggests 
that OSA increases oxidative and inflammatory 
processes on animal models and humans. No-
tably, chronic hypoxia-reoxygenation cycles due 
to intermittent hypoxia (IH) have been shown 
to promote the activation of inflammatory 
pathways (Lavie 2003, 35–51), such as increased 
pro-inflammatory cytokine production, meta-
bolic dysregulation and insulin resistance 
(Christou et al. 2003, 105–9; Ciftci et al. 2004, 
87–91). In addition, several markers of reactive 
oxidative species (ROS) are increased in OSA, 
amplifying inflammatory cascades and endothe-
lial dysfunctions, such as the development of 
atherosclerosis, as well as promoting central 
nervous system dysfunctions (Lavie 2003, 35–
51; Wang, Zhang and Gozal 2010, 307–16; 
Shelley X.L. Zhang, Wang and Gozal 2012, 
1767–77; Zhou et al. 2016, 9626831). 
Many clinical researches have clearly demon-
strated that acute IH, associated with the activa-
tion of the sympathetic nervous system and 
strictly linked to a persistent condition of oxida-
tive stress, represent the pathogenetic modali-
ties for the manifestation of cardiovascular 
comorbidities in OSA, such as systemic arterial 
hypertension, left ventricular hypertrophy, car-
diac rhythm alterations and, following associat-
ed early alterations of the vasal endothelium, 
with increased risk of cerebral stroke and myo-
cardial infarction. (Alchanatis et al. 2002, 1239–
45; Ameli et al. 2007, 729–34; Amin et al. 2002, 
1395–99; Brooks et al. 1997, 106–9; Lesske et 
al. 1997, 1593–1603; Varadharaj et al. 2015, 40–
47; Jose M Marin et al. 2005, 1046–53; Mason 
et al. 2012, 1791–98) 
Other studies have shown clear and solid asso-
ciations between OSA and HTN (Nieto et al. 
2000, 1829–36; Peppard et al. 2000, 1378–84; 
Phillips and O’Driscoll 2013, 43–52; Ren et al. 
2016, 1264–70), type II diabetes (Lai et al. 2016, 
543–51; Plíhalová, Westlake and Polák 2016, 
S79-84; Reichmuth et al. 2005, 1590–95), stroke 
(Arzt et al. 2005, 1447–51; Campos-Rodriguez 
et al. 2013, 99–105; Ifergane et al. 2016, 1207–
12), heart failure (Pearse and Cowie 2016, 353–
61; Cowie 2016, 255–65; Shahar and Whitney 
2001, 19–25), coronary heart disease (Loo et al. 
2014, 631–36; José M. Marin et al. 2012, 2169–
76; Selim, Won and Yaggi 2010, 203–20), cardi-
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ac arrhythmias (Vizzardi et al. 2017, 490–500), 
cancer (Campos-Rodriguez et al. 2013, 99–105), 
metabolic, neurodegenerative and respiratory 
diseases (Al Lawati, Patel and Ayas 2009, 285–
93; Caples, Garcia-Touchard and Somers 2007, 
291–303; Tahrani, Ali and Stevens 2013, 631–
38; Young et al. 2008, 1071–78). 
However, the factors determining the damage 
in a given OSA patient are not yet well defined, 
so research is still ongoing (Bhattacharjee et al. 
2011, 313–23; Leila Kheirandish-Gozal and 
Gozal 2013, 338–43; Tan, Kheirandish-Gozal 
and Gozal 2014, 474–80). 
 
Searching for new biomarkers 
 
Given the difficulty of applying Home Sleep 
Test (HST) to the population as a screening 
system due to high cost and examination tim-
ing, researchers are currently focusing on iden-
tifying new biomarkers for the early diagnosis 
of OSA (Mullington et al. 2016, 727–36).  
In 1998, the National Institutes of Health Bi-
omarkers defined a biomarker as an objectively 
measured feature evaluated as an indicator of 
normal biological or pathogenic processes, or 
either pharmacological responses to a therapeu-
tic intervention (Strimbu and Tavel 2010, 463–
66). Biomarkers can therefore provide infor-
mation for diagnosis, prognosis, regression or 
response to treatment. In this scenario, the -
OMIC sciences, such as genomics, tran-
scriptomics, proteomics, and metabolomics, 
have been widely applied for finding new bi-
omarkers in various disease mechanisms. The 
identification of such molecules involved in the 
pathogenesis of OSA patients, can facilitate ear-
ly diagnosis and help to understand the com-
plex mechanism of this disease.  
In the case of sleep disorders and lung diseases, 
traditional biomarker research techniques have 
proved to be not particularly performing. Stud-
ies based on proteomics (Zheng et al. 2015, 
7046; Jurado-Gamez et al. 2012, 139–46; Gozal 
et al. 2009, 1253–61) and metabolomics 
(Auffray et al. 2010, 1410–16; Davies et al. 
2014, 10761–66; Weljie et al. 2015, 2569–74; 
Giskeødegård et al. 2015, 14843) techniques in-
stead, have proven to be more sensitive, alt-
hough, to date, the number of molecules poten-
tially available for clinical application in the 
OSA context is still limited.. The development 
of new technologies is therefore necessary, also 
to provide a greater understanding of the bio-
chemical mechanisms involved in OSA. 
 
Proteomics Approach 
 
The study of the proteome in OSA patients has 
been largely assessed. Many studies have re-
ported that OSA patients express increased lev-
els of mediators of the systemic inflammatory 
response. Zhang et al. (Huina Zhang et al. 
2018, 97–108) have performed, for the first 
time, a proteomic approach to detect protein 
profiles of serum extracellular microvescicle 
proteins in OSA patients and in a chronic IH 
rodent model. Extracellular microvescicles are 
vescicles released from cells into the extracellu-
lar fluid environment, including serum. Their 
potential utility in clinical diagnosis is well doc-
umented, since vescicles are reported to reflect 
the physiological or pathological status of the 
tissue from which they arise. They found 4 dif-
ferentially expressed proteins in serum extracel-
lular microvescicles of OSA patients compared 
to control: C-reactive protein (CRP), Haptoglo-
bin (HP), Fibronectin (FN1), and Platelet factor 
4 (PF4). In addition, Nadeem et al., (Nadeem et 
al. 2013, 1003–12) have confirmed expressed 
level of CRP and other systemic inflammatory 
mediators, including intercellular adhesion mol-
ecules (ICAM), coagulation factors (factor VIII, 
tissue factor), and significant increase in serum 
levels of tumour necrosis factor alpha (TNF-α), 
interleukin 1β (IL-1β) and interleukin 6 (IL-6) 
were observed in patients with OSA. The ex-
cessive infiltration of inflammatory cells is also 
highlighted by the formation of subepithelial 
edema in OSA patients seen by histology. 
Among these proteins, circulating CRP is an 
important predictive factor of cardiovascular 
risk involved in the onset and progression of 
atherosclerosis. Its pro-inflammatory and 
proaterogenic properties have been found in 
endothelial cells, muscle cells, both smooth and 
striated, and macrophages.  Its levels, as well as 
those of IL-6, are strongly associated with oxi-
dative stress or anoxia (Nena et al. 2012, 181–
86; Huina Zhang et al. 2018, 97–108). A simi-
larly important role in the clinical picture of the 
OSA patient is the high level of TNF-α ob-
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served; it is in fact a pro-inflammatory cytokine 
with an important role in the defence of the 
host, which at the same time mediates the onset 
of a series of pathological processes such as 
atherosclerosis, septic shock and autoimmune 
diseases. The release of TNF-α is mediated by 
IL-6, as well as by other pro-inflammatory cy-
tokines such as IL-2, IL-2, IFN-γ and by TNF-
α itself through a positive feedback process 
(Aihara et al. 2013, 597–604; Dyugovskaya et al. 
2011, 154–62). 
A whole-genomic microarrays recently carried 
out by Yung-Che et al., has shown angiomotin 
(AMOT), pleckstrin homology, MyTH4 and 
FERM domain containing H3 (PLEKHH3), 
adenosine deaminase RNA specific (ADAR), 
baculoviral IAP repeat containing 3 (BIRC3), 
and galectin 3 (LGALS3) proteins over-
expressions in the treatment-naïve OSA pa-
tients (Chen et al. 2017). LGALS3 has shown to 
be involved in cancer, inflammation and fibro-
sis, heart disease, and stroke. Studies have also 
proved that the expression of galectin-3 is im-
plicated in a variety of processes associated with 
heart failure, including myofibroblast prolifera-
tion, fibrogenesis, tissue repair, inflammation, 
and ventricular remodelling (Henderson and 
Sethi 2009, 160–71; Sharma et al. 2004, 3121–
28; Liu et al. 2009, H404–12). 
Expression of AMOT in endothelial cells and 
its level is associated with proliferation and in-
vasion of breast tumours (Lv, Lv and Chen 
2015, 1938–46). 
ADAR are double chain RNA editing enzymes 
responsible for post-transcriptional modifica-
tion of mRNA transcripts by changing the nu-
cleotide content of the RNA. The conversion 
from A to I in the RNA disrupt the normal A:U 
pairing which makes the RNA unstable (Samuel 
2011, 180–93). ADAR is considered to be in-
volved in the insurgence of cancer (9). Studies 
in sleep field, revealed also that the ADA G22A 
polymorphism (c.22G>A, rs73598374) is asso-
ciated with fewer awakenings throughout the 
night, and a higher duration of slow wave sleep 
(SWS), as compared to the normal ADA G22G 
genotype (Milrad et al. 2014). 
BIRC3 is a downstream effector of the ubiqui-
tous hypoxia-inducible factor (HIF-1α) that is 
involved in pro-survival and inflammatory re-
sponses induced by the docosahexaenoic ac-
id/neuroprotectin D1 pathway under oxidative 
stress in an ischemia-reperfusion stroke model. 
HIF-1 α functions as a principle regulator activ-
ity of cellular and systemic homeostatic re-
sponse to hypoxia. This heterodimer composed 
of an alpha and a beta subunit can activate the 
transcription of many genes, including those 
involved in energy metabolism, apoptosis, angi-
ogenesis, and other genes whose protein prod-
ucts increase oxygen delivery and facilitate met-
abolic adaptation to hypoxia. Since many stud-
ies have shown that OSA is associated with an 
imbalance between oxidant production and an-
tioxidant activity, this fact, combined with an 
overabundance of oxidants can be linked to the 
multifactorial aetiology of metabolic disorders, 
including insulin resistance (Henriksen, Dia-
mond-Stanic and Marchionne 2011, 993–99).  
Almendros et al. (Almendros et al. 2018, 272) 
examined the correlation between HIF-1α fac-
tor and vascular endothelial growth factor 
(VEGF) expression in patients with cutaneous 
melanoma. Interestingly, they found that in a 
large prospective study, the expression of HIF-
1α was an independently factor associated with 
nocturnal IH measures of respiratory disturb-
ance during sleep in patients affected by cuta-
neous melanoma (Almendros et al. 2018, 272), 
this means that it has a significant contribution 
to the disease. Notably, the risk of melanoma 
was significantly higher in patients with OSA 
(HR = 1.14, 95% CI 1.10-1.18), along with 
pancreatic and kidney cancer (Gozal, Ham and 
Mokhlesi 2016, 1493–1500).  
In the recent years, other potential association 
between OSA and cancer have been reported, 
principally ascribed to IH effect on tumour bi-
ology (Gozal, Farré and Nieto 2016, 43–55; 
Gozal, Ham and Mokhlesi 2016, 1493–1500; 
Martínez-García, Campos-Rodriguez and Barbé 
2016, 451–63; Almendros et al. 2014, 593–601).  
A significant correlation between OSA and in-
creased cardiovascular risk and HTN is strongly 
reported in literature (Sjöström et al. 2002, 602–
7; Drager et al. 2010, 1135–39; Gami et al. 
2004, 364–67; Sin et al. 1999, 1101–6). Mass-
spectrometry was performed on salivary sam-
ples of OSA patients with cardiovascular dis-
eases (CVD) compared to non-CVD OSA pa-
tients (Zheng and Li 2014, 7046). A panel of 11 
biomarkers were identified to be differentially 
expressed between the two groups. They found 
that the alpha-2-HS-glycoprotein (AHSG) pep-
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tide level was significantly lower in OSA-CVD 
group compared to non-CVD group. Reduced 
level of AHSG was already found in severe 
OSA patients (Barceló et al. 2012, 1046–48) and 
at metabolic level  (Dyugovskaya et al. 2011, 
154–62) (see next chapter). AHSG protein is 
synthesized by hepatocytes and it is involved in 
severel process such as brain and bone for-
mation and endocytosis. Interestingly, lack of 
this protein is involved in leanness.  
Another studied association between OSA and 
HTN was performed by Koyama et al. (Koya-
ma et al. 2009, 1107–11). They studied 266 
OSA patients on respect to the Angiotensin 
converting enzyme (ACE) gene. This gene con-
tains an insertion/deletion polymorphism on 
the intron 16 characterized by a 287-bp DNA 
sequence (Alhenc-Gelas et al. 1991, 33–39). 
They showed that ACE II homozygote geno-
type protects from severe OSA in HTN pa-
tients.  
 
Metabolomics Approach 
 
The field of metabolomics, and the consequent 
search for potential biomarkers in OSA pa-
tients, is beginning to be explored only in re-
cent years. The lipidomic profile in OSA pa-
tients reported in literature, mainly reveals alter-
ation in the phospholipid biosynthesis and fatty 
acids expression. One of the major study 
through mass-spectrometry technique has al-
lowed to identify, both at a serum and urinery 
level, as many as 103 proteins differently ex-
pressed in adult OSA patients compared to 
controls, all potentially associated with imbal-
ances in lipid metabolism and alterations in the 
vascular system (Jurado-Gamez et al. 2012, 
139–46). Among phospholipids, glycerophos-
phocholines (PC), lysophosphatidylcholines 
(LPE), glycerophosphoethanolamines (PE), 
lysophosphatidylethanolamine (LPA), phos-
phoserine (PS), and lysophosphatidic acids, 
along with glycerophosphates (PA), monoacyl-
glycerophosphocholines, lyso-phosphocolyne 
(LPC) and sphingomyelin (SM) classes were 
found to be up regulated in patients with OSA 
compared to control (Ferrarini et al. 2013; Leb-
kuchen et al. 2018, 11270). Increased PC ex-
pression at salivary level was also reported 
through a LC-MS/MS methods (Kawai et al. 
2013; Engeli et al. 2012, 2345–51).  
Fatty acids alteration was also detected in OSA. 
Among those that significantly increased among 
OSA group compared to normal subjects, cir-
culating anandamide (AEA), 2,4-
dihydroxybutyric acid, 2-hydroxy-3-
methylbutyric acid, 3,4-dihydrxoybutyric acid, 
6-aminocaproic acid, pentanoic acid, and 
glyceraldehyde, 3-methyl-3-hydroxybutyric acid, 
and 4-hydroxypentenoic acid were up-
regulatetd, whereas the bile acid and gly-
cochenodeoxycholate-3-sulfate (GCDCA-3-
sulfate) decreased (Papandreou 2013, 569–72, 
Kawai et al. 2013; Engeli et al. 2012, 2345–51). 
Other groups, through GC-LC techniques, 
found that palmitoleic and oleic acid levels were 
lower, while stearic acid levels were higher in 
the tonsillitis tissue of infant control subjects, 
compared to the hyperplastic tissue typical of 
the diseased counterpart (Ezzedini et al. 2013, 
1008–12).  
Other research groups observed that in OSA 
patients, levels of 1/2-arachidonoylglycerols 
(AG), and oleoyl ethanolamide (OEA) in plas-
ma where higher when compared to controls. It 
was interesting to note that also AA arachidonic 
acid (AA) concentrations and eicosanoids (Fer-
rarini et al. 2013; Lebkuchen et al. 2018, 11270) 
were up-regulated in OSA patients, suggesting a 
role for the endocannabinoid system in regulat-
ing blood pressure in patients with high risk 
OSA for HTN and CVD (Kawai et al. 2013; 
Engeli et al. 2012, 2345–51). 
The endocannabinoid system is, in fact, based 
on lipid molecules produced by the body in re-
sponse to various stimuli that bind specific 
membrane receptors associated with the protein 
G and called cannabinoid receptors type 1 and 
2 (CB1 and CB2) (Pagotto, Vicennati and 
Pasquali 2008, 74S-82S). The endocannabinoid 
system represents a neuromodulation system, 
playing an action in the control of pain at the 
level of the central nervous system, in the regu-
lation of cell proliferation processes and in the 
modulation of the immune response. Interest-
ingly, it also seems to play a role in the mecha-
nisms that modulate appetite and therefore 
obesity (Di Marzo et al. 2001, 822–25; Crox-
ford and Yamamura; Marsicano et al. 2002, 
448–56; Engeli et al. 2012, 2345–51; Salzet et al. 
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2000, 4917–27). The endocannabinoid system 
also plays an important role in the release of ad-
ipokines. Recent research has shown that the 
pharmacological blockade of CB1 by an antag-
onist, named Rimonabant, stimulates the re-
lease of adiponectin, that is normally inhibited. 
Adiponectin is a circulating hormone secreted 
by adipose tissue, with antiaterogenic and anti-
diabetic properties that can reduce liver glucose 
production, as well as suppress lipogenesis and 
activate the oxidation of fatty acids (Matias et 
al. 2006, 3171–80; Jbilo et al. 2005, 1567–69). 
The endocannabinoid ways of regulating me-
tabolism are still only partially understood, de-
spite the fact that their role in controlling hun-
ger and satiety acts mainly in hypothalamic 
structures through the activation of neurons 
capable of producing neuropeptides with 
pressizing and anorexic action (Park and Bloom 
2005, 228–33). Alterations to the endocanna-
binoid system therefore affect and alter the en-
ergy metabolism of the body and the homeo-
stasis of lipids, as suggested by Di Marzo and 
Matias, the first to formulate the increasingly 
true hypothesis that obesity can be associated 
with a pathological hyperactivation of the en-
docannabinoid system (Di Marzo and Matias 
2005, 585–89). All these conditions can be as-
sociated with an increased risk of cardiometa-
bolic diseases such as type 2 diabetes, dyslipi-
daemia, arterial hypertension, myocardial infarc-
tion and stroke, conditions normally found in 
OSA patients. 
 
Mediators involved in systemic inflammatory 
response and oxidative stress were also report-
ed in OSA. Among the metabolites associated 
with oxidative stress, the 15-F2t-urinary iso-
prostane, one of the most sensitive metabolites 
correlated to lipid peroxidation, is positively 
linked to the thickness of the intimo-media ca-
rotid tunic (Paci et al. 2000, S87-91). These 
molecules were shown to be a specific, chemi-
cally stable, quantitative marker of oxidative 
stress in vivo. In particular, F2t-isoprostanes are 
prostaglandin isomers synthesised in vivo 
through the free radical catalysed peroxidation 
of AA in biological membranes, independently 
of the activity of cyclo-oxygenase (Morrow et 
al. 1990, 9383–87). Increased urinary excretion 
or plasma concentrations of 15-F2t-isoprostane 
has been observed in many conditions includ-
ing smoking, diabetes, and cardiovascular dis-
eases (Nonaka-Sarukawa et al.). 
Another important biomarker of oxidative 
stress, Malondialdehyde (MDA), is significantly 
higher in concentrations detected in patients 
with OSA than in controls (Denis Monneret et 
al. 2010, 619–25; Dikmenoğlu et al. 2006, 255–
61). MDA is the result of lipid peroxidation of 
polyunsaturated fatty acids. It is an important 
product in the synthesis of thromboxane A2 in 
which cyclooxygenase 1 or cyclooxygenase 2 
metabolizes AA into prostaglandin H2. ROS 
degrade polyunsaturated lipids, forming MDA 
(Gaweł et al. 2004, 453–55). This compound is 
a reactive aldehyde and is one of many reactive 
electrophilic species that cause toxic stress in 
cells, reacts with deoxyadenosine and deoxy-
guanosine in DNA, forming DNA adducts and 
can be used as a biomarker to measure the level 
of oxidative stress in an organism (Pryor and 
Stanley 1975, 3615–17; Marnett 1999, 83–95). 
 Arguably, the tricarboxylic acid cycle (TCA) 
and its mediators, tend to increase in OSA (Xu 
et al. 2016, 30958), suggesting augmenting of 
the oxidative stress.  
 
Among Metabolites that find space as pro-
inflammatory markers, Stanke-Labesque et al. 
have found Leucotriene E4 (U-LTE4), an in-
flammatory molecule associated with cysteinyl 
leukotriene production, whose elevation in uri-
nary concentration has been demonstrated in 
patients with OSA. Recently, Gautier-Veyret 
and his group have shown that this pathway ac-
tivation contributes to OSA-induced athero-
genesis and its blockade could represent a new 
therapeutic target for reducing CVD (Gautier-
Veyret et al. 2018, 311–19). It is also interesting 
to note that Continuous Positive Airway Pres-
sure (CPAP) treatment, a respiratory ventilation 
method mainly used in the treatment of sleep 
apnea, reduces the urinary concentration of U-
LTE4 by up to 22%, but only if the treatment is 
carried out in patients with a normal BMI 
(Stanke-Labesque et al. 2009, 364-370.e2).  
Arguably, CPAP treatment reduces also serum 
levels of Homocysteine (Hcy) by almost 30%, 
that, along with plasma levels, were found to be 
significantly higher in patients with OSA com-
pared to those of the controls (Ezzedini et al. 
2013, 1008–12; Papandreou 2013, 569–72, 
Fletcher et al. 1987, 35–44; Findley et al. 1988, 
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556–61). In addition, neural-like cell exposure 
to Hcy for a period of 5 days resulted in a 4.4-
fold increase in ROS production (Currò et al. 
2014, 1485–95). Hcy is known to mediate ad-
verse effects on cardiovascular endothelium 
and smooth muscle cells with resultant altera-
tions in subclinical arterial structure and func-
tion (Ganguly and Alam 2015, 6), leading to 
CVD and its complications, such as heart at-
tacks and strokes (Baszczuk and Kopczyński 
2014, 579–89). Moreover, hyperhomocyste-
inemia leads to enhancement of the adverse ef-
fects of risk factors like HTN, smoking, lipid 
and lipoprotein metabolism, as well as promo-
tion of the development of inflammation 
(Baszczuk and Kopczyński 2014, 579–89). An-
other study demonstrated that Hcy is capable of 
initiating an inflammatory response in vascular 
smooth muscle cells by stimulating CRP pro-
duction, which is mediated through NMDAr-
ROS-ERK1/2/p38-NF-κB signal pathway 
(Pang et al. 2014, 73–81). CRP expression was 
also found to be altered in the proteome of 
OSA patients (see previous chapter).  
Some studies also suggest that elevated Hcy 
levels may be associated with alterations in 
mental health such as cognitive impairment, 
dementia, depression, Alzheimer’s and Parkin-
son’s disease (Faeh, Chiolero and Paccaud 
2006, 745–56; Carmel and Jacobsen 2001) 
through its capacity to act as a neurotransmit-
ter. In particular, Hcy may act either as a partial 
agonist at glutamate receptors or as a partial an-
tagonist of glycine co-agonist site of the 
NMDA receptor, therefore in the presence of 
normal glycine levels and normal physiological 
conditions, Hcy does not cause toxicity but in 
case of a head trauma or stroke, there is an ele-
vation in glycine levels in which instance the 
neurotoxic effect of Hcy as an agonist out-
weighs its neuroprotective antagonist effect. 
This neuronal damage following a stroke has 
been attributed to the over stimulation of excit-
atory amino acids such as glutamate and aspar-
tate through activation of NMDA receptors 
(Ganguly and Alam 2015, 6; Carmel and Jacob-
sen 2001). Ganguly et al. (Ganguly and Alam 
2015, 6) have investigated how Hcy is able to 
selectively stimulate the release of these excita-
tory amino acids in stroke and they concluded 
that they may trigger the release of catechola-
mine, resulting into detrimental effect in brain 
and cardiovascular system. Interestingly, in 
OSA patients, glutamate metabolites were also 
found to be significantly altered  (Xu et al. 
2016, 30958). 
The study of catecholamine metabolites and de-
rivatives as potential predictors of the onset of 
the pathological process seems particularly 
promising. Fletcher et al. (Fletcher et al. 1987, 
35–44), for example, observed that norepineph-
rine (NE) and normethanephrine levels were 
significantly higher in the urine of patients with 
OSA than those found in obese HTN controls, 
as well as epinephrine (E) levels, at the plasma 
level (Findley et al. 1988, 556–61). Data subse-
quently confirmed by Paci et al. (Paci et al. 
2000, S87-91), who also found higher levels of 
dopamine (DA) in the comparison of 10 male 
patients with OSA and 11 controls. HPLC ob-
servations revealed a significant increase in all 
urinary catecholamine in OSA children, and 
that the levels of NE and E during the night are 
strongly related to the severity with which they 
manifest the altered phenotype. Paik et al (Paik 
et al. 2014, 517–23), after studies carried out us-
ing GC-MS to detect metabolites of urinary 
neurotransmitters, demonstrated that homo-
vanillic acid (HVA) and 3,4-
dihydroxyphenylacetic acid (DOPAC), both 
dopamine metabolites, were increased in sleepy 
patients with OSA, suggesting that excessive 
daytime sleepiness in these subjects is probably 
caused by an increase in night-time activity of 
the dopaminergic and sympathetic systems 
(O’Driscoll et al. 2011, 483–88). Although this 
theory seems intriguing, the results of several 
other studies question it. Paci et al. have report-
ed that E and DA levels did not vary signifi-
cantly between OSA patients and controls. In 
addition, the results of the studies of Gislason 
et al, found 5-hydroxyindo-lacetic acid (5-
HIAA), HVA and 3-methoxy-4-hydroxyphe-
glicolenyl glycol (MHPG) in the cerebrospinal 
fluid of 15 patients with OSA and 18 controls; 
however, even in this case, the levels of all these 
biomarkers were similar in patients with OSA 
and control subjects (Paci et al. 2000, S87-91; 
Gislason et al. 1992, 784–86).  
The inconsistency of the results obtained from 
the studies on catecholamine metabolites in pa-
tients with OSA may be due to various factors 
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such as the heterogeneity of the analytical plat-
forms used by the various research groups, the 
different biological matrices taken into account, 
the small size of the samples, and the different 
protocols used for sample collection. Elements 
that may also affect the reproducibility of stud-
ies.  
 
The first studies aimed at finding differentially 
expressed metabolites at the urinary level in 
children with OSA, was carried out by Krishna 
et al. (Krishna et al. 2006, 221–27). They adopt-
ed a mass-spectrometry technique on a cohort 
of 22 subjects, who demonstrated an alteration 
in the glomerular and tubular filtration of the 
kidneys, compared to the healthy counterpart. 
High levels of proteins such as jasmine, per-
lecan (a heparan sulfate proteoglycan), albumin, 
and immunoglobulin were detected in urine. 
Result which suggested increased catabolic ac-
tivity of some proteins in OSA patients (Krish-
na et al. 2006, 221–27). Also in the same period, 
Shah et al. identified at the silky level, three pro-
teins of 5896, 3306 and 6068 kDa respectively 
differently expressed in pathological children, 
capable of discriminating the latter from healthy 
patients with 90% specificity and 93% sensitivi-
ty (Shah et al. 2006, 466–70). Three years later, 
Gozal et al., through a method based on the use 
of 2D-DIGE-MS, were able to identify 16 me-
tabolites differently expressed in the urine of 
OSA patients compared to controls. In particu-
lar, the analysis of concentrations of some of 
these, including uromodulin, urocortin-3, oro-
somucoid-1, and kallikrein, were able to identify 
the pathogenic phenotype with a sensitivity of 
95% and even a specificity of 100% (Gozal et 
al. 2009, 1253–61).  
The contribution of Seetho et al. and Zeng et 
al. in the field of research into potential OSA 
biomarkers was extremely interesting, with the 
first, focusing on the research of polypeptides 
using the urine of obese OSA patients used as a 
biological matrix, and the second, looking for 
proteins differently expressed between OSA pa-
tients suffering from CVD and not, in saliva. 
The work of the two groups allowed identifying 
27 potential biomarkers, fibrinogen alpha chain 
(FGA), tubulin alpha-4A chain (TUBA4A) and 
AHSG. More specifically, AHSG has been 
shown to be expressed at lower levels in OSA 
frameworks associated with changes in cardio-
vascular function (Seetho et al. 2014, 1104–15; 
Zheng and Li 2014, 7046). 
 
Alteration in the amino acid biosynthesis were 
also reported in OSA through metabolomics 
approach. Xu et al. identified 21 differentially 
expressed urinary metabolites among simple 
snoring group and control, including aspartyl-
serine, isoleucine-threonine (Ile-Thr), and me-
thionine, whereas levels of 3-hydroxyanthranilic 
acid and 5-hydroxytryptophan decreased. Hy-
droxyprolyl-methionine, hypoxanthine, Ile-Thr, 
indole-3-acetamide, isoleucine, lactic acid, myo-
inositol, pentanoic acid, threitol, threoninyl-
methionine, trimethylamine N-oxide (TMAO), 
uridine, and valine were consistently higher or 
lower (Xu et al. 2016, 30958). Other groups 
have also reported that methylcysteine and ser-
ine decreased in OSA condition (Kawai et al. 
2013; Engeli et al. 2012, 2345–51).  
 
The metabolomics profiling of spermine bio-
synthesis, indoles and tryptophan metabolism, 
tyrosine metabolism as well as porphyrin me-
tabolism were also altered significantly  (Xu et 
al. 2016, 30958; Papandreou 2013, 569–72).  
 
Conclusions 
 
OSA is characterized by recurrent episodes of 
collapse of the upper airways during sleep, 
which are reflected in a desaturation of haemo-
globin that leads to the awakening of affected 
subjects. The chronic IH registered in this con-
dition, leads the body to enact molecular adap-
tations to the low-oxygen conditions to which it 
is subject (Young et al. 1993, 1230–35). Despite 
this, sleep fragmentation results in a dangerous 
condition of excessive sleepiness during the rest 
of the day. In addition to the long-term prob-
lems that are listed, this sleep fragmentation en-
tails a daily danger for the individual linked to 
the increased risk of road or work accidents. 
The body responds to chronic fatigue through 
compensatory mechanisms that evoke inflam-
matory responses, hyperactivation of the sym-
pathetic system and alteration of endothelial 
function, like regulation of tight junctions; these 
events have an important role in promoting the 
onset of atherosclerosis and, in the long run, of 
cardiovascular and cerebrovascular diseases 
(Nadeem et al. 2013, 1003–12). 
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Recent studies show also a significant correla-
tion between OSA and metabolic and neu-
rocognitive risk (Sjöström et al. 2002, 602–7; 
Drager et al. 2010, 1135–39; Gami et al. 2004, 
364–67; Sin et al. 1999, 1101–6), as well as an 
association with cancer mortality. 
In literature, proteomics and metabolomics ap-
proaches were used to detect change in physio-
logical or pathological status of OSA patients 
compared to controls, in order to find out new 
mediators that can be used as biomarkers of the 
disease. Notwithstanding OSA is a ‘quite new’ 
emerging disease, there are lots of proteins and 
metabolites that arise during disease, in particu-
lar those involved in inflammation and oxida-
tive stress, in line with the clinical IH that pa-
tient undertaken in OSA disease.  
Lipid dismetabolism in OSA reflects alteration 
in phospholipids biosynthesis, steroidogenesis 
and fatty acids expression. This may influence 
the cell membrane formation, incrementing li-
pid uptake, atherogenesis and inflammation.  In 
addition, alterations in amino acids, nucleic acid 
and some mediators that act as neurotransmit-
ters, such as Hcy and the endocannabinoid sys-
tem were seen in OSA patients, suggesting an 
increased risk of cardiometabolic diseases such 
as type 2 diabetes, dyslipidaemia, arterial hyper-
tension, myocardial infarction and stroke, con-
ditions normally found in OSA patients. 
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